Motif Bio PLC Appointments of U.S. finance adviser and auditor (8221M)

TIDMMTFB

RNS Number : 8221M

Motif Bio PLC

25 January 2016

Motif Bio plc

("Motif" or the "Company")

Appointments of U.S. corporate finance adviser and auditor

Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces today the appointment of U.S. healthcare investment bank MTS Health Partners (MTS) to advise on its future financing options within the U.S. market. A NASDAQ listing continues to be an option for Motif in order to be aligned with several peer companies.

The Company has appointed as its auditor PricewaterhouseCoopers LLP (PwC), one of the top four multinational professional services firms in the world.

Considerable progress has also been made with plans to identify strategic partners who are interested in licensing our Phase III asset, iclaprim, outside the U.S.

Graham Lumsden, CEO of Motif, said: "For Motif to continue to grow and become a leading antibiotic company, and in order to continue to build value for our existing shareholders, it is important that we explore the capital markets in the U.S., including the potential for a NASDAQ listing. With the appointment of MTS, we can make the right decisions on how to proceed during 2016.

"The accomplishments in 2015 - listing on AIM in April, raising GBP25 million including the follow-on in July, being granted QIDP designation for iclaprim by the FDA, and completing the manufacture of clinical trial supplies, have strengthened the Company and positioned us for continued success in 2016."

Enquiries:

 
 Motif Bio plc                          info@motifbio.com 
  Graham Lumsden (Chief Executive 
  Officer) 
  www.motifbio.com 
 Zeus Capital Limited (NOMINATED 
  ADVISER and BROKER) 
  Phil Walker/Dan Bate                  +44 (0) 20 
  Dominic Wilson                         3829 5000 
 Northland Capital Partners Limited 
  (BROKER) 
  Patrick Claridge/ David Hignell       +44 (0) 20 
  John Howes (Broking)                   7382 1100 
 
 
                                          +49 (0) 89 
   MC Services AG (TRADE PR)              210 2280 
   Raimund Gabriel                        +44 (0) 207 
   Shaun Brown                            148 5998 
 Plumtree Capital Limited (FINANCIAL 
  ADVISOR)                              +44 (0) 207 
  Stephen Austin                         183 2493 
 Yellow Jersey PR Limited (FINANCIAL 
  PR) 
  Charles Goodwin                       +44 (0) 7747 
  Dominic Barretto                       788 221

Notes to Editors:

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif please visit www.motifbio.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUSUKRNOAAUAR

(END) Dow Jones Newswires

January 25, 2016 02:00 ET (07:00 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024